Development of new N-arylbenzamides as STAT3 dimerization inhibitors†
Abstract
The
* Corresponding authors
a
Departments of Drug Discovery, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
E-mail:
Nicholas.Lawrence@moffitt.org
Fax: +1 813 745 6748
Tel: +1 813 745 6037
b Departments of Chemical Biology Core, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
c Departments of Oncologic Sciences, University of South Florida, Tampa, FL 33620, USA
d Departments of Chemistry, University of South Florida, Tampa, FL 33620, USA
e Departments of Molecular Medicine, University of South Florida, Tampa, FL 33620, USA
The
M. K. Urlam, R. Pireddu, Y. Ge, X. Zhang, Y. Sun, H. R. Lawrence, W. C. Guida, S. M. Sebti and N. J. Lawrence, Med. Chem. Commun., 2013, 4, 932 DOI: 10.1039/C3MD20323A
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content